LFWD Lifeward Ltd.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1607962 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-14.1%
TTM net income YoY-9.6%
TTM EPS YoY74.7%
Revenue 3-yr CAGR32.0%
Net income 3-yr CAGR—
Margins
Gross margin31.5%
Operating margin-121.5%
Net margin-155.4%
FCF margin-93.3%
EBITDA margin-120.2%
Returns
ROE-326.8%
ROA-121.9%
ROIC (approx.)-308.2%
Asset turnover0.78x
Leverage & solvency
Liabilities / assets76.2%
Debt / equity0.00x
Current ratio2.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-48.8%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $22.03M | $25.66M |
| Cost of revenue | $13.61M | $17.45M |
| Gross profit | $8.43M | $8.22M |
| R&D expense | $3.25M | $4.62M |
| SG&A expense | $8.20M | $5.20M |
| Operating income | -$19.67M | -$29.35M |
| Pretax income | -$19.97M | -$28.90M |
| Income tax | -$55,000 | $43,000 |
| Net income | -$19.91M | -$28.94M |
| EBITDA | -$19.34M | -$28.85M |
| EPS (basic) | -17.16 | -39.96 |
| EPS (diluted) | -17.16 | -39.96 |
| Weighted avg. shares (diluted) | 1.16M | 724,272 |
| Banking | ||
| Net interest income | -$312,000 | $643,000 |
| Balance sheet | ||
| Cash & equivalents | $2.17M | $7.11M |
| Receivables | $6.14M | $6.00M |
| Inventory | $5.73M | $6.72M |
| Current assets | $15.81M | $21.29M |
| PP&E, net | $585,000 | $867,000 |
| Goodwill | $4.75M | $7.54M |
| Intangibles | — | $0 |
| Total assets | $22.90M | $30.49M |
| Current liabilities | $12.04M | $10.22M |
| Total liabilities | $14.49M | $11.64M |
| Shareholders' equity | $8.41M | $18.85M |
| Shares outstanding | 1.52M | 733,966 |
| Cash flow statement | ||
| Operating cash flow | -$16.83M | -$21.72M |
| Capital expenditure | $16,000 | $0 |
| Free cash flow | -$16.84M | -$21.72M |
| Investing cash flow | -$16,000 | $0 |
| Financing cash flow | $12.20M | $0 |
| Depreciation & amortization | $333,000 | $494,000 |
| Stock-based compensation | $743,000 | $1.28M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.